Malaria drug hydroxyc
roquine showed no benefit in a large study of its use at U.S. veterans hospitals, researchers say.
Hydroxyc
roquine has garnered global attention during the coronavirus pandemic, most notably from President Trump, who touted it as a potential treatment.
The research, which was published in the medRxiv online depository, evaluated data from 368 COVID-19 patients.
CLINICAL TRIAL OF POTENTIAL CORONAVIRUS TREATMENT HYDROXYCHLOROQUINE BEGINS, NIH SAYS
“We performed a retrospective analysis of data from patients hospitalized with confirmed SARS-CoV-2 infection in all United States Veterans Health Administration medical centers until April 11, 2020,” the researchers explained. Some 97 patients had been treated with just hydroxycholoroquine, 113 were treated with hydroxycholoroquine and the antibiotic azithromycin and 158 received “standard supportive management” for COVID-19.
COVID-19 treatment hydroxyc
roquine showed no benefit, more deaths in VA virus study

Hydroxyc

The research, which was published in the medRxiv online depository, evaluated data from 368 COVID-19 patients.
CLINICAL TRIAL OF POTENTIAL CORONAVIRUS TREATMENT HYDROXYCHLOROQUINE BEGINS, NIH SAYS
“We performed a retrospective analysis of data from patients hospitalized with confirmed SARS-CoV-2 infection in all United States Veterans Health Administration medical centers until April 11, 2020,” the researchers explained. Some 97 patients had been treated with just hydroxycholoroquine, 113 were treated with hydroxycholoroquine and the antibiotic azithromycin and 158 received “standard supportive management” for COVID-19.
COVID-19 treatment hydroxyc
